Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy

Abstract

Background: A major, yet precisely studied, shift has occurred in the treatment of advanced hormone-sensitive prostate cancer (HSPC) by the addition of docetaxel to androgen deprivation therapy (ADT) in the first line. Recently, two landmark trials showed that abiraterone acetate (AA) can be an effective alternative along with ADT in the same setting. We implemented a network meta-analysis to compare the safety and efficacy of the two combinations.

Methods: PubMed database, ASCO and ESMO meeting library databases of all results published until June 2017 were searched using the keywords: “prostate cancer” AND “docetaxel” OR “abiraterone acetate”. Efficacy endpoints including progression-free survival (PFS) and overall survival (OS), and safety endpoints (including treatment related deaths and selected adverse events) were assessed.

Results: Twenty relevant studies were retrieved and assessed for eligibility. Of those trials, eight were found potentially eligible. Inconsistent reporting of efficacy outcomes limited our analysis to M1 HSPC. The pooled hazard ratios (HRs) of OS and PFS of the direct comparison of abiraterone acetate plus ADT versus ADT were 0.63 (95% CI: 0.545–0.717) and 0.38 (95% CI: 0.34–0.43), respectively. Meanwhile, in the trials of docetaxel plus ADT the pooled HRs of OS and PFS were 0.75 (95% CI: 0.65–0.86) and 0.634 (95% CI: 0.57–0.70), respectively. The indirect comparison showed that the HRs of OS and PFS in DOC + ADT in comparison to AA + ADT were 1.2 (95% CI: 0.98–1.46) and 1.65 (1.40–1.94), respectively. The pooled RR of treatment-related mortality in docetaxel + ADT versus AA + ADT was 1.438 (95% CI: 0.508–4.075).

Conclusion: Patients with metastatic HSPC (mHSPC) who received abiraterone acetate with ADT had better PFS and less toxicity compared to those receiving docetaxel with ADT. A trend towards superior OS and fewer treatment-related deaths was also observed, but was statistically non-significant. In view of lacking clear OS advantage, the choice between docetaxel and AA should include a discussion with the patient about the potential toxicities and impact on quality of life of each regimen.

Keywords:

• Hormone-sensitive prostate cancer
• abiraterone acetate
• docetaxel
• efficacy
• safety

Transparency

Declaration of funding

This manuscript was not funded.

Author contributions: The study was designed by O.A. K.S.S. and O.A. conducted the literature review and data extraction. When disagreement existed, L.K. was referred to for settlement of conflict. L.K. and O.A. evaluated the included RCTs’ quality. K.S.S. and L.K. wrote the Methods and Results. All authors contributed to writing the Discussion and approving the final version of the manuscript.

Declaration of financial/other relationships

L.K., K.S.S. and O.A. have disclosed that they have no significant relationships with or financial interests in any commercial companies related to this study or article.

CMRO peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Acknowledgments

None reported.